The Health Effects Effects of Colorful Bioactive Pigments: Comparison
View Latest Version
Please note this is a comparison between Version 2 by Conner Chen and Version 1 by Michelle Blumfield.

Inadequate intake of fruits and vegetables (FV) is a leading modifiable dietary risk factor for mortality and contributes to the increasing burden of both communicable and non-communicable diseases. Despite the unequivocal health benefits of eating FV, 78% of adults worldwide do not consume the daily recommended servings [14], leading to a ‘phytonutrient gap’. Naturally occurring and pigmented phytonutrients (herein referred to as bioactive pigments) give FV their vibrant colors and correspond to one or more phytonutrient categories; e.g., red corresponds to lycopene, yellow to alpha-carotene, orange to beta-carotene, green to chlorophyll, purple and blue to anthocyanins, and white to flavones.

  • fruit
  • vegetables
  • color
  • health
  • phytochemicals
  • carotenoids
  • flavonoids
  • chlorophyll

1. Health Effects of Red Pigments in Fruits and Vegetables

Data on the effect of red bioactive pigments were from beta-cryptoxanthin (n  = 15 SLRssystematic literature reviews (SLRs) reporting n  = 33 MAsmeta-analyses (MAs)) and lycopene (n = 25 SLRs of n = 65 MAs). Anthocyanins may also be red in an acidic environment, but were reported with the blue/purple bioactive pigments [38][1].

1.1. Beta-Cryptoxanthin

Only two of the included MAs on beta-cryptoxanthin were based on randomized controlled trials (RCTs) data (12-weeks; 6 mg/day; mixed sources of beta-cryptoxanthin), and the remaining 31 MAs were based on cohort data (1–26 years). Most cohort MAs compared an unspecified highest category with the lowest; however, where the highest categories were specified, they provided 56–200 µg/day compared with the lowest at <1.8 to 20 µg/day. Cohort data were derived from diet (n = 21 MAs), mixed sources (n = 3 MAs), or serum levels (n = 7 MAs); and included seven dose–response MAs.
The highest category of beta-cryptoxanthin intake was associated with a 28% decreased risk of hip fracture (OR 0.72; 95% CI 0.60, 0.87) [39][2] and up to a 27% decreased risk of all-cause mortality (RR 0.73; 95% CI, 0.58, 0.88) [40][3], compared to the lowest category of intake. A small effect was also found for the inflammatory biomarker C-reactive protein (CRP; MD −0.35 mg/L; 95% CI −0.54, −0.15), after individuals consumed 6 mg beta-cryptoxanthin over 12-weeks [37][4].
In relation to cancer, the highest category of dietary beta-cryptoxanthin intake was associated with a 69% decreased risk of larynx cancer (OR 0.41; 95% CI 0.33, 0.51) [41][5], 64% decreased risk of oral cavity and pharynx cancer (OR 0.46; 95% CI 0.29, 0.74) [41][5], 42% decreased risk of bladder cancer (RR 0.58; 95% CI 0.36, 0.94) [42][6], and 20% decreased risk of lung cancer (RR 0.80; 95% CI 0.72, 0.89) [43][7], compared to the lowest category of intake.
In dose–response MAs of serum levels, each 0.1 mg/day increase in beta-cryptoxanthin, decreased the risk of all-cause mortality by 6% (RR 0.94; 95% CI 0.89, 0.99) [40][3], whereas for every daily increase of 0.5 µmol/L, the risk of type 2 diabetes (T2DM) decreased by 15% (RR 0.85; 95% CI 0.76, 0.94) [44][8].
No differences were found for beta-cryptoxanthin and risk of: cataracts [45][9], early age-related macular degeneration [46][10], osteoporosis [39][2], Parkinson’s disease [47][11], non-Hodgkin lymphoma [48][12], breast cancer [29][13], colorectal cancer [49][14], pancreatic cancer [50][15] or lung cancer mortality [43][7].
The strongest evidence for the health effect of beta-cryptoxanthin was for a decreased risk of all-cause mortality (dose–response relationship, moderate to large effect size, GRADE: very low), bladder cancer (dose–response relationship, very large effect size, GRADE: medium), oral, laryngeal, or pharyngeal cancer (very large effect size, GRADE: very low to medium), and T2DM (dose–response relationship, large effect size, GRADE: low).

1.2. Lycopene

There was n = 14 MAs included based on RCT data (1-day to 6-months duration; 2–50 mg/day); with the remaining n = 51 MAs based on observational cohort data (3-months to 26-years duration; 2035–10,000 µg/day), n = 11 of which were dose–response MAs (per 1000 µg/day or incremental serum levels). Most MAs analyzed dietary intake data (n = 32 MAs), followed by mixed sources (n = 22 MAs), serum values (n = 10 MAs), and one MA measured supplemental intake.
The highest category of dietary lycopene intake was associated with reductions in the risk of cervical (OR 0.54; 95% CI, 0.39, 0.75) [51][16], larynx (OR 0.50; 95% CI, 0.28, 0.89) [41][5], lung (RR 0.71; 95% CI, 0.51, 0.98) [43][7], oral cavity and pharynx (OR 0.74; 95% CI, 0.56, 0.98) [41][5] and prostate (RR 0.88; 95% CI, 0.79, 0.99) [34][17] cancers, compared to the lowest category of dietary lycopene intake. Reductions in the risk of breast cancer were only reported in case control studies, where greater reductions in risk up to 29% (OR 0.71; 95% CI, 0.56, 0.92) [29][13] were found with greater dietary lycopene intake.
Higher lycopene intake was also associated with cardiovascular improvements with small to moderate clinical significance, including a lower risk of CHD (RR 0.87; 95% CI, 0.76, 0.98) [52][18], cardiovascular disease (CVD) (HR 0.86; 95% CI 0.77, 0.95) [53][19], stroke (HR 0.74; 95% CI 0.62, 0.89) [53][19], T2DM (RR 0.85; 95% CI 0.76, 0.96) [44][8], mortality (HR 0.63; 95% CI 0.49, 0.81) [53][19] and all-cause mortality (RR 0.72; 95% CI 0.49, 0.95) [40][3]. In dose–response MAs of serum levels, each 0.5 µmol/L increase in serum lycopene decreased the risk of T2DM by 17% (RR 0.83; 95% CI 0.74, 0.92) [44][8].
Lycopene status had no effect on preeclampsia [54][20], early age-related macular degeneration [46][10], risk of hip fracture [55][21], advanced prostate cancer [34,56][17][22], colon/colorectal/rectal cancer [49][14], bladder cancer [42][6], gastric cancer [57][23], non-Hodgkin lymphoma [48][12], ovarian cancer [58][24], Parkinson’s disease [47][11], inflammatory biomarkers (except a small effect in interleukin-6 (MD −1.08 pg/mL; 95% CI −2.03, −0.12) [37][4], lipid profiles [59[25][26],60], blood pressure [60][26] and prostate specific antigen (PSA) levels [61][27].
The strongest evidence for the health effects of lycopene were decreased risk of breast cancer (dose–response relationship, large to very large effect size, GRADE: very low) and T2DM (dose–response relationship, moderate to large effect size, GRADE: very low to low).

2. Health Effects of Orange Pigments in Fruits and Vegetables

The health effects of consuming orange bioactive pigments from FV were reported by MAs of beta-carotene (bioactive pigment subclass; n = 34 SLRs reporting n = 75 MAs including n = 16 dose–response MAs).
Evidence for the effects of beta-carotene was largely represented by MAs of cohort studies (n = 59 MAs) measured over 1–26 years via dietary intake (n = 32 MAs), mixed sources (n = 16 MAs), serum levels (n = 10 MAs) or supplementation (n = 1 MA). Doses in the highest categories of intake were not usually reported, but when reported ranged from 2473–7000 µg/day intake or 16 to >120 µg/dL serum level. The one supplemental study provided a dose of 600 to 1991 µg/day. Sixteen of the observational MAs were dose–response, examining effects per 500–5000 µg/day intake or per 0.1 µmol/L serum level.
The highest category of beta-carotene intake was associated with a decreased risk of several types of cancers, including cervical (OR 0.68; 95% CI 0.55, 0.84) [51][16], gastric (OR 0.74; 95% CI 0.61, 0.91) [62][28], larynx (OR 0.43; 95% CI 0.24, 0.77) [41][5], non-Hodgkin lymphoma (RR 0.80; 95% CI 0.68, 0.94) [48][12], oral cavity (OR 0.54; 95% CI 0.37, 0.80) [41][5], ovarian (RR 0.84; 95% CI 0.75, 0.94) [63][29] and pancreatic (OR 0.78; 95% CI 0.66, 0.92) [50][15] cancers, compared to the lowest category of beta-carotene intake. Reductions in breast cancer risk were supported by dose–response MAs that found dietary beta-carotene intakes of 2000 µg/day, 3000 µg/day or 5000 µg/day reduced the risk of breast cancer by 3%, 4% and 7%, respectively [29][13]. For each 1000 µg/1000 kcal increase in dietary beta-carotene the risk of endometrial cancer decreased by 26% (RR 0.74; 95% CI 0.61, 0.91) [64][30].
Highest categories of beta-carotene intake were also associated with a lower risk of all-cause mortality (RR 0.82; 95% CI 0.77, 0.86) [40][3], coronary heart disease (CHD) (RR 0.73; 95% CI 0.65, 0.82) [65][31], CVD mortality (RR 0.68; 95% CI 0.52, 0.83) [66][32], total fracture (RR 0.63; 95% CI 0.52, 0.77) [67][33], hip fracture (OR 0.72; 95% CI 0.54, 0.95) [55][21] and the incidence of cataract (RR 0.90; 95% CI 0.83, 0.99) [45][9] and preeclampsia (SMD −0.40; 95% CI −0.72, −0.08) [54][20], when compared to the lowest intakes. In dose–response MAs, each 1 mg/day increase in beta-carotene intake decreased the risk of all-cause mortality by 5% (OR 0.95; 95% CI 0.92, 0.99) [40][3], whereas for every 0.5 µmol/L serum increase the risk of T2DM decreased by 35% (OR 0.65; 95% CI 0.48, 0.89) [44][8].
No differences were found for dietary beta-carotene and risk of bladder cancer [42][6], colon cancer [49][14], colorectal cancer [49][14], lung cancer [43][7], lung cancer or lung cancer mortality [43][7], melanoma [68][34], prostate cancer [56[22][28],62], rectal cancer [49][14], COPD [69][35], total fracture [70][36] and Alzheimer’s disease [71][37].
The strongest evidence for the health effects of beta-carotene were decreased risk of all-cause and CVD mortality (dose–response relationship, very large effect size, GRADE: very low to low), T2DM (dose–response relationship, large to very large effect size, GRADE: low to medium), bladder cancer (dose–response relationship, very large effect size, GRADE: very low), breast cancer (dose–response relationship, large effect size, GRADE: very low to low) and endometrial cancer (dose–response relationship, large effect size, GRADE: very low).

3. Health Effects of Yellow Bioactive Pigments in Fruits and Vegetables

The evidence for the health effects of yellow bioactive pigments were from MAs reporting on alpha-carotene (n = 16 SLRs reporting n = 41 MAs), lutein (n = 7 SLRs reporting n = 10 MAs), zeaxanthin (n = 2 SLRs reporting n = 3 MAs) or lutein and zeaxanthin as a combined group (n = 13 SLRs reporting n = 31 MAs).

3.1. Alpha-Carotene

All n = 41 MAs reporting on the health effects of alpha-carotene were based on cohort and/or case–control research, measured via dietary intake (n = 27 MAs with 1–25 years follow-up); serum levels (n = 10 MAs with 2–26 years follow-up); or mixed diet, serum levels, and/or supplements (n = 4 MAs with 9-months to 26-years follow-up). Most MAs compared an unspecified highest category against the unspecified lowest category; however, some category groups were defined as >881–2000 µg/day compared against <180 to 300 µg/day dietary intake or serum levels of >1 to >5 µg/dL compared against <1 to <2 µg/dL.
The highest category of alpha-carotene intake was associated with a reduced risk of gastric (OR 0.58; 95% CI 0.44, 0.76) [57][23], non-Hodgkin lymphoma (RR 0.87; 95% CI 0.78, 0.97) [48][12], oral cavity and pharynx (OR 0.57; 95% CI 0.41, 0.79) [41][5] and prostate (RR 0.87; 95% CI 0.76, 0.99) [56][22] cancers, and a reduced risk of T2DM (RR 0.91; 95% CI 0.85, 0.96) [44][8] and all-cause mortality (RR 0.79; 95% CI, 0.63, 0.94) [40][3]. In dose–response MAs, for each 1000 µg/day increase in alpha-carotene the risk of breast cancer decreased by up to 18% (RR 0.82; 95% CI 0.73, 0.93) [29][13] and the risk of non-Hodgkin lymphoma decreased by 13% (RR 0.87; 95% CI 0.78, 0.97) [48][12].
Alpha-carotene intake was reported to have no effect on risk of pre-eclampsia [54][20], cataract [45][9], early aged-related macular degeneration [46][10], cancer of the larynx [41][5], risk of colon, rectal, or colorectal cancer [49][14], hip fracture [55][21], lung cancer [43][7], pancreatic cancer [50][15] or Parkinson’s disease [47][11].
The strongest evidence for the health effects of alpha-carotene were decreased risk of all-cause mortality (dose–response relationship, large effect size, GRADE: very low to low), bladder cancer (dose–response relationship, very large effect size, GRADE: high), non-Hodgkin lymphoma (dose–response relationship, moderate to large effect size, GRADE: very low) and T2DM (dose–response relationship, large to very large effect size, GRADE: medium).

3.2. Lutein

All n = 10 MAs reporting on the health effects of lutein drew upon cohort or case–control data, measured via dietary intake (n = 4 MAs with 10–12 years follow-up), serum levels (n = 2 MAs with 8–10 years follow-up) or mixed sources (n = 4 MAs with 9-months to 26-years follow-up). Most of the MAs compared the highest unspecified category of lutein to the lowest unspecified category; however, one highest category was defined as 3701 to 4041 µg/day compared to 1413 to 1736 µg/day dietary intake.
When compared to the lowest category, the highest category of lutein intake improved the risk of stroke by 18% (RR 0.82; 95% CI 0.58, 0.78) [72][38] and the risk of T2DM by 35% (RR 0.65; 95% CI 0.55, 0.77). In dose–response MAs of serum levels, each 0.2 ugmol/L increase in lutein decreased the risk of T2DM by 21% (RR 0.79; 95% CI 0.72, 0.86). Lutein was reported to have no effect on risk of lung cancer [43][7], gastric cancer [57][23], Parkinson’s disease [47][11], pre-eclampsia [54][20] or all-cause mortality [40][3]
The strongest evidence for the health effects of lutein was for decreased risk of T2DM (dose–response relationship, large to very large effect size, GRADE: medium).

3.3. Zeaxanthin

All three MAs which measured the effect of zeaxanthin on human health were based on cohort studies, with n = 2 MAs based on serum zeaxanthin levels (8–10 years follow-up) and n = 1 MA based on mixed sources (2–26 years follow-up). When comparing the highest unspecified category against the lowest unspecified category, zeaxanthin had no effect on all-cause mortality [40][3] or risk of T2DM [44][8].

3.4. Lutein and Zeaxanthin

Thirty-one MAs investigated the effect of combined lutein and zeaxanthin on human health, n = 29 of which were based on cohort of case–control studies, and n = 2 were based on RCTs. The observational research primarily measured lutein and zeaxanthin via dietary intake (n = 22 MAs with 1–25 years follow-up) or serum levels (n = 5 MAs with 2–26 years follow-up), with only one MA considering mixed sources (5–18 years follow-up). Only n = 3 MAs defined the intake of lutein and zeaxanthin in the highest category (>1815 to 5000 µg/day) as compared to the lowest category (<775 to 1000 µg/day). The two RCT MAs both considered dietary or supplemental intake of lutein and zeaxanthin with interventions ranging from 8–32 weeks and doses of 8 mg/day to 27 mg/day.
When comparing the highest category versus lowest category of lutein and zeaxanthin status, higher dietary intakes reduced the risk of non-Hodgkin lymphoma by 18% (RR 0.82; 95% CI 0.69, 0.97) [48][12], while higher serum intakes reduced the risk of bladder cancer (RR 0.53; 95% CI 0.33, 0.84) [42][6] and all-cause mortality (RR 0.85; 95% CI 0.74, 0.97) [40][3]. Lutein and zeaxanthin intakes were associated with decreased CRP levels (SMD −0.3 mg/L; 95% CI −0.45, −0.15) [37][4] and a dose–response relationship found a favorable 17% decreased risk of breast cancer for every 3000 µg/day increase in lutein and zeaxanthin intake (RR 0.83; 95% CI 0.77, 0.89) [29][13]. Dose–response relationships were not found for any other level of lutein or zeaxanthin intake.
For lutein and zeaxanthin, no differences were found for the risk of gastric cancer [57][23], lung cancer [43][7], lung cancer or lung cancer mortality [43][7], pancreatic cancer [50][15], oral cavity and pharynx cancer [41][5], colon [49][14], rectal [49][14] or colorectal cancer [49][14], early aged macular degeneration [46][10], hip fracture [55][21] or IL-6 [37][4].
The strongest evidence for combined lutein and zeaxanthin was for decreased risk of bladder cancer (dose–response relationship, large to very large effect size, GRADE: low to high) and breast cancer (dose–response relationship, large effect size, GRADE: very low to low).

4. Health Effects of Pale-Yellow Bioactive Pigments in Fruits and Vegetables

The health effects of consuming pale yellow bioactive pigments from FV were reported by MA of flavonols (bioactive pigment subclass; n = 17 SLRs reporting n = 33 MAs), kaempferol (n = 1 SLR reporting n = 1 MA), myricetin (n = 1 SLR reporting n = 2 MA), and quercetin (n = 10 SLRs reporting n = 25 MAs).

4.1. Flavonols

As a group, MAs of flavonols subclass were primarily based on cohort and/or case–control data (n = 25 MAs with 2–28 years follow-up); although there was substantial cause-and-effect investigation via n = 8 MAs of RCTs (14–84 days intervention duration). Over half (n = 14 of 25) of the observational MAs measured flavonols from dietary sources alone (1–27 years follow-up), with the remaining n = 11 MAs measuring flavonols from mixed sources (4–28 years follow-up). The doses of intake in the highest or lowest categories were not reported. Four of the observational MAs were dose–response, examining effects per 10 mg or 20 mg, and were based on cohort data. All the MAs based on RCTs tested the effect of flavonols delivered via supplementation from 14- to 90-days at doses of 6–1000 mg.
When comparing the highest intake or levels with the lowest, flavonols were found to improve the risk of stroke (RR 0.86; 95% CI 0.75, 0.96), CVD (RR 0.85; 95% CI 0.79, 0.91), and CHD (RR 0.88; 95% CI, 0.79, 0.98), as well as CVD- (RR 0.79; 95% CI 0.63, 0.99) and CHD-related death (RR 0.80; 95% CI 0.69, 0.93) [73,74,75,76,77][39][40][41][42][43]. High categories of flavonols were also associated with a reduced risk of T2DM (RR 0.92; 95% CI 0.85, 0.98) [78][44] and risk of breast (RR 0.88; 95% CI 0.80, 0.96), colorectal (RR 0.71; 95% CI 0.63, 0.81), gastric (OR 0.80; 95% CI 0.70, 0.91), ovarian (RR 0.68; 95% CI 0.58, 0.80) and smoking related cancer (OR 0.77; 95% CI 0.63, 0.95) [79,80,81,82,83][45][46][47][48][49]. However, two other MAs found no association with breast cancer [84][50], one found no association with CHD [85][51], and no differences were found for effect on all-cause mortality [73][39], hypertension [86][52] or other types of cancer including liver, lung, pancreatic, esophageal or prostate [84,87,88][50][53][54].
In dose–response MAs, for each 20 mg/day increase in flavonols the risk of stroke decreased by 14% (RR 0.86; 95% CI 0.77, 0.96) [77][43], and for each 10 mg/day increase in flavonols the risk of CVD mortality decreased by 13% (RR 0.87; 95% CI 0.76, 0.99) [73][39]. MAs of RCTs examined chronic disease indicators, finding supplementation with flavonols improved systolic (MD −3.05 mmHg; 95% CI −4.83, −1.27) and diastolic (MD −2.63 mmHg; 95% CI −3.83, −1.42) blood pressure, HDL cholesterol (MD 0.05 mmol/L; 95% CI 0.02, 0.07), low density lipoprotein (LDL) cholesterol (MD −0.14 mmol/L; 95% CI −0.21, −0.07), and total cholesterol (MD −0.11 mmol/L; 95% CI −0.20, −0.02), blood glucose (MD −0.18 mmol/L; 95% CI −0.29, −0.08) and triglycerides (MD −0.11 mmol/L; 95% CI −0.18, −0.03) [89][55]; however, there was no effect on waist circumference [90][56].

4.2. Kaempferol, Quercetin and Myricetin

One SLR reported on highest versus lowest dietary intake of kaempferol, quercetin, and myricetin using case–control data (duration not reported) [84][50]; whereas the nine other SLRs reported on 30–1000 mg/day of supplemental quercetin via MA of RCTs (5-days to 12-weeks duration) [91,92,93,94,95,96,97,98,99][57][58][59][60][61][62][63][64][65]. There were no dose–response MAs.
When comparing the highest dietary intake with the lowest, kaempferol, but not myricetin or quercetin, reduced the risk of lung cancer by 23% (RR 0.77; 95% CI 0.62, 0.97) [84][50]. Supplemental quercetin improved a range of CVD risk factors, including systolic (MD −3.09 mmHg; 95% CI −4.83, −1.27) and diastolic blood pressure (MD −2.86 mmHg; 95% CI −5.09, −0.63) [93][59], CRP (MD −0.33 mg/L; 95% CI −0.50, −0.16) [94][60], VO2 max (MD 1.94%; 95% CI 0.30, 3.59) [97][63] and exercise performance (MD 2.82%; 95% CI 2.05, 3.58) [99][65]. RCT evidence for quercetin found no effect on blood lipids [91[57][59],93], glycemic or insulin metabolism [95][61], other measures of inflammation [96,98][62][64] or adiposity [92][58].
The strongest evidence for the health effect of flavonols and flavonols sub-classes was for improved blood pressure (cause-and-effect relationship established, large effect size, GRADE: low to high), cholesterol (cause-and-effect relationship established, small effect size, GRADE: low to high), blood glucose (cause-and-effect relationship established, small effect size, GRADE: medium) and risk of CVD or CHD mortality (dose–response relationship, very large effect size, GRADE: medium) and stroke (dose–response relationship, moderate to large effect size, GRADE: very low).

5. Health Effects of White Bioactive Pigments in Fruits and Vegetables

The evidence for the health effects of white bioactive pigments were from MAs reporting on flavones. All n = 19 MAs for flavones were based on cohort data (1–24 years duration) as measured via the diet (n = 13 MAs) or mixed sources (n = 6 MAs), and two MAs were dose–response analyses. The highest category of flavones was associated with a decreased risk of all-cause (RR 0.86; 95% CI 0.80, 0.93) and CVD mortality (RR 0.85; 95% CI 0.75, 0.96) [84][50], breast cancer (RR 0.81; 95% CI 0.68, 0.96) [83[49][50],84], CHD (RR 0.94; 95% CI 0.89, 0.99) [74][40], esophageal cancer (OR 0.78; 95% CI 0.64, 0.95) [87][53], liver cancer (RR 0.49; 95% CI 0.30, 0.78) [84][50] and smoking-related cancer (OR 0.77; 95% CI 0.69, 0.85) [80][46]. In dose–response MAs, for each 1 mg/day increase in flavones, the risk of CVD mortality decreased by 7% (RR 0.93; 95% CI 0.90, 0.97) [84][50]. No differences were found for hypertension [86][52], risk of CVD [76][42], risk of T2DM, or risk of colorectal [79][45], lung [82[48][50],84], ovarian [84][50], pancreatic [84][50] or prostate cancer [88][54].
The strongest evidence for the health effect of flavones was for decreased risk of all-cause and CVD mortality (dose–response relationship, moderate to large effect size, GRADE: very low to low), liver cancer (very large effect size, GRADE: medium) and smoking-related cancers (moderate effect size, GRADE: medium).

6. Health Effects of Purple/Blue Bioactive Pigments in Fruits and Vegetables

Purple/blue bioactive pigments were contributed to by anthocyanidins, anthocyanins, proanthocyanidins and proanthocyanins.

6.1. Anthocyanidins

All n = 7 MAs examining anthocyanidins were based on cohort data derived from the diet (n = 2 MAs, 4–20 years duration) or mixed sources (n = 5 MAs, 4–16 years duration). The highest and lowest categories were not defined, but the single dose–response MA analyzed effects per 10 mg/day.
Higher anthocyanidin serum levels were associated with an 11% decrease in both all-cause (RR 0.89; 95% CI 0.85, 0.94) and CVD mortality (RR 0.89; 95% CI 0.83, 0.95). In dose–response MAs, for each 10 mg/day increase in anthocyanidins the risk of CVD mortality improved by 6% (RR 0.94; 95% CI 0.88, 0.99) [73][39]. Greater anthocyanidin intake was also associated with a 32% decreased risk of colorectal cancer (RR 0.68; 95% CI 0.56, 0.82) [79][45], 14% decreased risk of T2DM (HR 0.86; 95% CI 0.81, 0.91) [78][44], but a 12% increased risk of prostate cancer (RR 1.12; 95% CI 1.03, 1.21) [88][54]. No association was found for smoking-related cancer [80][46].

6.2. Anthocyanins

Most anthocyanin research was based on RCTs (n = 67 MAs) derived from diet (n = 19 MAs of 3-days to 6-weeks duration; dose not reported), mixed sources (n = 32 MAs of 4-h to 6-months duration, dose 1.3–1025 mg/day) or supplementation (n = 16 MAs of 1–96 weeks duration, dose 1.6–1323 mg/day). The n = 14 cohort MAs measured anthocyanins from the diet (n = 11 MAs, 1–24 years duration, dose not reported) or mixed sources (n = 3 MAs, 5–41 years, dose not reported).
The highest category of anthocyanin intake was associated with a decreased risk of CVD (RR 0.82; 95% CI 0.70, 0.96) [76][42], CHD (RR 0.90; 95% CI 0.83, 0.98) [74][40], CVD mortality (RR 0.92; 95% CI 0.87, 0.97) [100][66], hypertension (RR 0.92; 95% CI 0.88, 0.97) [86][52] and esophageal cancer (OR 0.60; 95% CI 0.49, 0.74) [87][53]. However, no association was found with risk of stroke [100][66], or multiple cancers including breast, liver, lung, pancreatic or gastric [83,84,101][49][50][67].
Thirty-three of the n = 67 (49%) RCT MAs reported improved inflammatory, oxidative, lipid, or glycemic markers (e.g., adiponectin, apolipoprotein A1/B, CRP, fasting glucose, HbA1c, HOMA-IR, LDL and HDL cholesterol, interleukin-6, tumor necrosis factor alpha (TNF-alpha), triglycerides) [26[67][68][69][70][71],101,102,103,104], as well as vascular reactivity (SMD 0.77; 95% CI 0.37, 1.16) [105][72] and body mand BMIss index (BMI) (SMD −0.36 kg/m2; 95% CI −0.58, −0.13) [27][73]. No improvements were found for liver enzymes [106][74], uric acid, blood pressure [107][75], waist circumference [107][75], delayed onset muscle soreness [101][67] or vascular stiffness [105][72].
The strongest evidence for the health effect of anthocyanins and anthocyanidins was for improved inflammatory and oxidative stress biomarkers (cause-and-effect relationship established, small to large effect size, GRADE: very low to low), glycemic and insulinemic biomarkers (cause-and-effect relationship established, small effect size, GRADE: medium), lipid profiles and vascular function (cause-and-effect relationship established, small to large effect size, GRADE: very low to medium) and adiposity (cause-and-effect relationship established, small effect size, GRADE: low to medium).

6.3. Proanthocyanidins

There were n = 11 MAs which reported on the effects of proanthocyanidins (n = 4 RCT MAs, n = 7 cohort MAs). Proanthocyanidin RCT MAs were all based on supplemental interventions of 100–400 mg/day delivered over 5 to 16 weeks. Cohort MAs were delivered over 4–16 years with unspecified categories of highest and lowest intakes, measured via diet (n = 3 MAs) or mixed sources (n = 4 MAs). One of the n = 7 cohort MAs was a dose–response analyses examining effects per 100 mg/day.
The highest serum levels of proanthocyanidin compared with the lowest was associated with a 11% improvement in CVD mortality risk (RR 0.89; 95% CI 0.81, 0.97), but this was not significant in a dose–response analysis [84][50]. Higher status was also associated with a 28% decreased risk of colorectal cancer (RR 0.72; 95% CI 0.61, 0.85) [79][45]. No differences were found with risk of all cause-mortality, T2DM, breast cancer or esophageal cancer [73,78,87][39][44][53]. MAs of RCT evidence showed that supplemental proanthocyanidin (100–400 mg for 5–16 weeks) improved systolic (MD −4.60 mmHg; 95% CI −8.04, −1.16) and diastolic (MD −2.75 mmHg; 95% CI −5.09, −0.41) blood pressure and mean arterial pressure (MD −3.37 mmHg; 95% CI −6.72, −0.01), but not pulse pressure [108][76].

6.4. Proanthocyanins

The two MAs of proanthocyanins were based on cohort data and measured the highest dietary intakes compared with the lowest for up to 16 years, and found an inverse association with risk of CVD (RR 0.83; 95% CI 0.73, 0.95) [76][42] and CHD (RR 0.78; 95%CI 0.65, 0.94) [74][40].
The strongest evidence for the health effect of proanthocyanidins and proanthocyanins was for decreased blood and arterial pressure (large effect size, GRADE: high).

7. Health Effects of Green Bioactive Pigments in Fruits and Vegetables

The health effects of consuming green bioactive pigments from FV were reported by single RCT and cohort evidence for chlorophyll. Ten of the seventeen health outcome measures reported for chlorophyll were based on RCT data (Sweden and Japan, 8–12 weeks of 0.7–3000 mg supplementation/day); the remaining seven were from cohort data (Netherlands, 9-years duration, highest undefined quintile). One RCT reported chlorophyll supplementation improved seasonal allergic rhinitis rescue medication scores (MD −3.09; 95% CI −5.96, −0.22) [109][77] and 3000 mg supplementation per day trended towards 1.5 kg weight loss; however, this appeared underpowered (p = 0.06, n = 36 participants) [110][78]. RCT evidence reported no effect on other measures of body composition or levels of insulin, glucose, or leptin [110][78]. Analysis of cohort data found no association between the highest intakes of chlorophyll and colorectal, colon or rectal cancer [111][79].

8. Health Effects Unique to Each Bioactive Pigment

Many health outcomes were improved by three or more bioactive pigments, such as a decreased risk of all-cause mortality with the highest intakes of lycopene, beta-cryptoxanthin, beta-carotene, alpha-carotene, lutein and zeaxanthin, flavones and anthocyanin/anthocyanidin. Other improved health outcomes which were associated with three or more bioactive pigment colors were body weight; total cholesterol/lipid profiles; inflammatory biomarkers; CVD, CHD, CVD mortality; stroke; T2DM; and multiple cancers including breast, oral, lung, prostate, bladder, colorectal/colon/rectal and gastric.
Some health effects were unique to only one or two bioactive pigments or colors. Every FV bioactive pigment color had a single highly unique health effect which was not associated with any other pigment color, except red and yellow (Table 21). For example, only red bioactive pigments were associated with a decreased risk of pancreatic and laryngeal cancer, and only pale-yellow pigments were associated with improved exercise performance. All bioactive pigment colors also had other unique health effects that were associated with only two bioactive pigment colors. For example, decreased risk of cervical cancer was associated with only red and orange bioactive pigments, and decreased risk of esophageal cancer was only associated with white and blue/purple bioactive pigments (Table 21).
Table 21.
 Unique health effects of bioactive pigment colors found in fruit or vegetables.
Bioactive Pigment Color Highly Unique Health Effects a,c Unique Health Effects b,c
Red/orange/yellow ↑ cognitive function

(GRADE: medium)

↓ risk of ischemic heart disease (IHD)

(GRADE: very low)

↑ HDL cholesterol

(GRADE: high)

↓ waist circumference

(GRADE: low to medium)		  
Red   ↓ risk of cervical cancer

(GRADE: very low)

↓ risk of lung cancer

(GRADE: very low)

↓ risk of pancreatic cancer

(GRADE: very low)

↓ risk of pharyngeal cancer

(GRADE: very low to medium)

↓ risk of hip fracture

(GRADE: very low)

↓ risk of laryngeal cancer

(GRADE: very low to medium)
Orange ↓ risk of preeclampsia

(GRADE: very low)

↓ risk of total fracture

(GRADE: very low)

↓ endometrial cancer

(GRADE: very low)		 ↓ risk of non-Hodgkin lymphoma (GRADE: very low)

↓ risk of ovarian cancer

(GRADE: very low)

↓ risk of cervical cancer

(GRADE: very low)

↓ risk of pancreatic cancer

(GRADE: very low)

↓ risk of cataract

(GRADE: very low)

↓ risk of hip fracture

(GRADE: very low)

↓ risk of laryngeal cancer

(GRADE: very low to medium)
Yellow   ↓ risk of non-Hodgkin lymphoma (GRADE: very low)

↓ risk of cataract

(GRADE: very low)

↓ risk of pharyngeal cancer

(GRADE: very low)
Pale-yellow ↑ exercise performance

(GRADE: very low)		 ↓ risk of ovarian cancer

(GRADE: low)

↓ risk of cervical cancer

(GRADE: very low)

↓ blood pressure

(GRADE: low to high)

↓ glycemic biomarkers

(GRADE: medium)

↓ risk of smoking-related cancers (GRADE: very low)
White ↓ risk of liver cancer

(GRADE: medium)		 ↓ risk of smoking-related cancers (GRADE: medium)

↓ risk of esophageal cancers

(GRADE: very low)
Blue/purple ↓ risk of hypertension

(GRADE: very low)

↓ oxidative stress biomarkers

(GRADE: very low to low)

↓ insulinemic biomarkers

(GRADE: medium)

↓ vascular function

(GRADE: very low to medium)

↓ arterial pressure

(GRADE: high)		 ↓ glycemic biomarkers

(GRADE: medium)

↓ risk of esophageal cancers

(GRADE: very low)

↓ blood pressure

(GRADE: high)
Green ↓ seasonal rhinitis

(GRADE: N/A)		  
a A health effect was considered highly unique if it was found to be associated with a single bioactive pigment color. b A health effect was considered unique if it was found to be associated with only two bioactive pigment colors. c  GRADE working groups of evidence: high = further research is unlikely to change our confidence in the estimated effect; medium = further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low = further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low = we are very uncertain about the estimate.
Of the highly unique health effects (i.e., significant effect in a single color of FV), only four outcomes have been confirmed as being truly unique by being tested for association with three or more different bioactive pigments. Waist circumference, unique to carotenoids, was found not to be affected by anthocyanins nor flavonols; risk of hypertension, unique to anthocyanins, was found to have no association with flavones nor flavonols; risk of preeclampsia, unique to beta-carotene, was found to have no association with alpha-carotene, lutein nor lycopene; and risk of liver cancer, unique to flavones, was found to have no association with anthocyanins nor flavanols (Table 21). The remaining highly unique health effects reported in Table 21 were only tested for association with one or two bioactive pigments, and it is therefore unknown if they may be improved by other bioactive pigments also.

References

  1. Khoo, H.E.; Azlan, A.; Tang, S.T.; Lim, S.M. Anthocyanidins and anthocyanins: Colored pigments as food, pharmaceutical ingredients, and the potential health benefits. Food Nutr. Res. 2017, 61, 1361779.
  2. Kim, S.J.; Anh, N.H.; Diem, N.C.; Park, S.; Cho, Y.H.; Long, N.P.; Hwang, I.G.; Lim, J.; Kwon, S.W. Effects of β-Cryptoxanthin on Improvement in Osteoporosis Risk: A Systematic Review and Meta-Analysis of Observational Studies. Foods 2021, 10, 296.
  3. Jayedi, A.; Rashidy-Pour, A.; Parohan, M.; Zargar, M.S.; Shab-Bidar, S. Dietary Antioxidants, Circulating Antioxidant Concentrations, Total Antioxidant Capacity, and Risk of All-Cause Mortality: A Systematic Review and Dose-Response Meta-Analysis of Prospective Observational Studies. Adv. Nutr. 2018, 9, 701–716.
  4. Hajizadeh-Sharafabad, F.; Zahabi, E.S.; Malekahmadi, M.; Zarrin, R.; Alizadeh, M. Carotenoids supplementation and inflammation: A systematic review and meta-analysis of randomized clinical trials. Crit. Rev. Food Sci. Nutr. 2021, 1–17.
  5. Leoncini, E.; Nedovic, D.; Panic, N.; Pastorino, R.; Edefonti, V.; Boccia, S. Carotenoid Intake from Natural Sources and Head and Neck Cancer: A Systematic Review and Meta-analysis of Epidemiological Studies. Cancer Epidemiol. Biomark. Prev. 2015, 24, 1003–1011.
  6. Wu, S.; Liu, Y.; Michalek, J.E.; Mesa, R.A.; Parma, D.L.; Rodriguez, R.; Mansour, A.M.; Svatek, R.; Tucker, T.C.; Ramirez, A.G. Carotenoid Intake and Circulating Carotenoids Are Inversely Associated with the Risk of Bladder Cancer: A Dose-Response Meta-analysis. Adv. Nutr. 2020, 11, 630–643.
  7. Gallicchio, L.; Boyd, K.; Matanoski, G.; Tao, X.; Chen, L.; Lam, T.K.; Shiels, M.; Hammond, E.; Robinson, K.A.; Caulfield, L.E.; et al. Carotenoids and the risk of developing lung cancer: A systematic review. Am. J. Clin. Nutr. 2008, 88, 372–383.
  8. Jiang, Y.W.; Sun, Z.H.; Tong, W.W.; Yang, K.; Guo, K.Q.; Liu, G.; Pan, A. Dietary Intake and Circulating Concentrations of Carotenoids and Risk of Type 2 Diabetes: A Dose-Response Meta-Analysis of Prospective Observational Studies. Adv. Nutr. 2021.
  9. Jiang, H.; Yin, Y.; Wu, C.-R.; Liu, Y.; Guo, F.; Li, M.; Ma, L. Dietary vitamin and carotenoid intake and risk of age-related cataract. Am. J. Clin. Nutr. 2019, 109, 43–54.
  10. Chong, E.W.; Wong, T.Y.; Kreis, A.J.; Simpson, J.A.; Guymer, R.H. Dietary antioxidants and primary prevention of age related macular degeneration: Systematic review and meta-analysis. BMJ 2007, 335, 755.
  11. Takeda, A.; Nyssen, O.P.; Syed, A.; Jansen, E.; Bueno-De-Mesquita, B.; Gallo, V. Vitamin A and carotenoids and the risk of parkinson’s disease: A systematic review and meta-analysis. Neuroepidemiology 2013, 42, 25–38.
  12. Chen, F.; Hu, J.; Liu, P.; Li, J.; Wei, Z.; Liu, P. Carotenoid intake and risk of non-Hodgkin lymphoma: A systematic review and dose-response meta-analysis of observational studies. Ann. Hematol. 2017, 96, 957–965.
  13. Hu, F.; Wang Yi, B.; Zhang, W.; Liang, J.; Lin, C.; Li, D.; Wang, F.; Pang, D.; Zhao, Y. Carotenoids and breast cancer risk: A meta-analysis and meta-regression. Breast Cancer Res. Treat. 2012, 131, 239–253.
  14. Panic, N.; Nedovic, D.; Pastorino, R.; Boccia, S.; Leoncini, E. Carotenoid intake from natural sources and colorectal cancer: A systematic review and meta-analysis of epidemiological studies. Eur. J. Cancer Prev. 2017, 26, 27–37.
  15. Huang, X.; Gao, Y.; Zhi, X.; Ta, N.; Jiang, H.; Zheng, J. Association between vitamin A, retinol and carotenoid intake and pancreatic cancer risk: Evidence from epidemiologic studies. Sci. Rep. 2016, 6, 38936.
  16. Myung, S.K.; Ju, W.; Kim, S.C.; Kim, H. Vitamin or antioxidant intake (or serum level) and risk of cervical neoplasm: A meta-analysis. BJOG 2011, 118, 1285–1291.
  17. Rowles, J.L., 3rd; Ranard, K.M.; Smith, J.W.; An, R.; Erdman, J.W., Jr. Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017, 20, 361–377.
  18. Song, B.; Liu, K.; Gao, Y.; Zhao, L.; Fang, H.; Li, Y.; Pei, L.; Xu, Y. Lycopene and risk of cardiovascular diseases: A meta-analysis of observational studies. Mol. Nutr. Food Res. 2017, 61.
  19. Cheng, H.M.; Koutsidis, G.; Lodge, J.K.; Ashor, A.W.; Siervo, M.; Lara, J. Lycopene and tomato and risk of cardiovascular diseases: A systematic review and meta-analysis of epidemiological evidence. Crit. Rev. Food Sci. Nutr. 2019, 59, 141–158.
  20. Cohen, J.M.; Beddaoui, M.; Kramer, M.S.; Platt, R.W.; Basso, O.; Kahn, S.R. Maternal Antioxidant Levels in Pregnancy and Risk of Preeclampsia and Small for Gestational Age Birth: A Systematic Review and Meta-Analysis. PLoS ONE 2015, 10, e0135192.
  21. Xu, J.; Song, C.; Song, X.; Zhang, X.; Li, X. Carotenoids and risk of fracture: A meta-analysis of observational studies. Oncotarget 2017, 8, 2391–2399.
  22. Wang, Y.; Cui, R.; Xiao, Y.; Fang, J.; Xu, Q. Effect of Carotene and Lycopene on the Risk of Prostate Cancer: A Systematic Review and Dose-Response Meta-Analysis of Observational Studies. PLoS ONE 2015, 10, e0137427.
  23. Zhou, Y.; Wang, T.; Meng, Q.; Zhai, S. Association of carotenoids with risk of gastric cancer: A meta-analysis. Clin. Nutr. 2016, 35, 109–116.
  24. Li, X.; Xu, J. Meta-analysis of the association between dietary lycopene intake and ovarian cancer risk in postmenopausal women. Sci. Rep. 2014, 4, 4885.
  25. Ried, K.; Fakler, P. Protective effect of lycopene on serum cholesterol and blood pressure: Meta-analyses of intervention trials. Maturitas 2011, 68, 299–310.
  26. Tierney, A.C.; Rumble, C.E.; Billings, L.M.; George, E.S. Effect of dietary and supplemental lycopene on cardiovascular risk factors: A systematic review and meta-analysis. Adv. Nutr. 2020, 11, 1453–1488.
  27. Ilic, D.; Forbes, K.M.; Hassed, C. Lycopene for the prevention of prostate cancer. Cochrane Database Syst. Rev. 2011, Cd008007.
  28. Druesne-Pecollo, N.; Latino-Martel, P.; Norat, T.; Barrandon, E.; Bertrais, S.; Galan, P.; Hercberg, S. Beta-carotene supplementation and cancer risk: A systematic review and metaanalysis of randomized controlled trials. Int. J. Cancer 2010, 127, 172–184.
  29. Huncharek, M.; Klassen, H.; Kupelnick, B. Dietary beta-carotene intake and the risk of epithelial ovarian cancer: A meta-analysis of 3,782 subjects from five observational studies. In Vivo 2001, 15, 339–343.
  30. Bandera, E.V.; Gifkins, D.M.; Moore, D.F.; McCullough, M.L.; Kushi, L.H. Antioxidant vitamins and the risk of endometrial cancer: A dose-response meta-analysis. Cancer Causes Control 2009, 20, 699–711.
  31. Mente, A.; de Koning, L.; Shannon, H.S.; Anand, S.S. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. Arch. Intern. Med. 2009, 169, 659–669.
  32. Jayedi, A.; Rashidy-Pour, A.; Parohan, M.; Zargar, M.S.; Shab-Bidar, S. Dietary and circulating vitamin C, vitamin E, β-carotene and risk of total cardiovascular mortality: A systematic review and dose-response meta-analysis of prospective observational studies. Public Health Nutr. 2019, 22, 1872–1887.
  33. Charkos, T.G.; Liu, Y.; Oumer, K.S.; Vuong, A.M.; Yang, S. Effects of β-carotene intake on the risk of fracture: A Bayesian meta-analysis. BMC Musculoskelet. Disord. 2020, 21, 711.
  34. Zhang, Y.P.; Chu, R.X.; Liu, H. Vitamin A intake and risk of melanoma: A meta-analysis. PLoS ONE 2014, 9, e102527.
  35. Seyedrezazadeh, E.; Moghaddam, M.P.; Ansarin, K.; Asghari Jafarabadi, M.; Sharifi, A.; Sharma, S.; Kolahdooz, F. Dietary Factors and Risk of Chronic Obstructive Pulmonary Disease: A Systemic Review and Meta-Analysis. Tanaffos 2019, 18, 294–309.
  36. Zhang, X.; Zhang, R.; Moore, J.B.; Wang, Y.; Yan, H.; Wu, Y.; Tan, A.; Fu, J.; Shen, Z.; Qin, G.; et al. The Effect of Vitamin A on Fracture Risk: A Meta-Analysis of Cohort Studies. Int. J. Environ. Res. Public Health 2017, 14, 1043.
  37. Li, F.J.; Shen, L. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer’s disease: A meta-analysis. J. Alzheimer’s Dis. 2012, 31, 253–258.
  38. Leermakers, E.T.; Darweesh, S.K.; Baena, C.P.; Moreira, E.M.; Melo van Lent, D.; Tielemans, M.J.; Muka, T.; Vitezova, A.; Chowdhury, R.; Bramer, W.M.; et al. The effects of lutein on cardiometabolic health across the life course: A systematic review and meta-analysis. Am. J. Clin. Nutr. 2016, 103, 481–494.
  39. Grosso, G.; Micek, A.; Godos, J.; Pajak, A.; Sciacca, S.; Galvano, F.; Giovannucci, E.L. Dietary Flavonoid and Lignan Intake and Mortality in Prospective Cohort Studies: Systematic Review and Dose-Response Meta-Analysis. Am. J. Epidemiol. 2017, 185, 1304–1316.
  40. Fan, Z.K.; Wang, C.; Yang, T.; Li, X.Q.; Guo, X.F.; Li, D. Flavonoid subclasses and coronary heart disease risk: A meta-analysis of prospective cohort studies. Br. J. Nutr. 2021, 1–34.
  41. Huxley, R.R.; Neil, H.A. The relation between dietary flavonol intake and coronary heart disease mortality: A meta-analysis of prospective cohort studies. Eur. J. Clin. Nutr. 2003, 57, 904–908.
  42. Micek, A.; Godos, J.; Del Rio, D.; Galvano, F.; Grosso, G. Dietary Flavonoids and Cardiovascular Disease: A Comprehensive Dose-Response Meta-Analysis. Mol. Nutr. Food Res. 2021, 65, e2001019.
  43. Wang, Z.M.; Zhao, D.; Nie, Z.L.; Zhao, H.; Zhou, B.; Gao, W.; Wang, L.S.; Yang, Z.J. Flavonol intake and stroke risk: A meta-analysis of cohort studies. Nutrition 2014, 30, 518–523.
  44. Rienks, J.; Barbaresko, J.; Oluwagbemigun, K.; Schmid, M.; Nöthlings, U. Polyphenol exposure and risk of type 2 diabetes: Dose-response meta-analyses and systematic review of prospective cohort studies. Am. J. Clin. Nutr. 2018, 108, 49–61.
  45. Woo, H.D.; Kim, J. Dietary flavonoid intake and risk of stomach and colorectal cancer. World J. Gastroenterol. 2013, 19, 1011–1019.
  46. Woo, H.D.; Kim, J. Dietary flavonoid intake and smoking-related cancer risk: A meta-analysis. PLoS ONE 2013, 8, e75604.
  47. Xie, Y.; Huang, S.; Su, Y. Dietary Flavonols Intake and Risk of Esophageal and Gastric Cancer: A Meta-Analysis of Epidemiological Studies. Nutrients 2016, 8, 91.
  48. Hua, X.; Yu, L.; You, R.; Yang, Y.; Liao, J.; Chen, D.; Yu, L. Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis. PLoS ONE 2016, 11, e0151134.
  49. Hui, C.; Qi, X.; Qianyong, Z.; Xiaoli, P.; Jundong, Z.; Mantian, M. Flavonoids, flavonoid subclasses and breast cancer risk: A meta-analysis of epidemiologic studies. PLoS ONE 2013, 8, e54318.
  50. Grosso, G.; Godos, J.; Lamuela-Raventos, R.; Ray, S.; Micek, A.; Pajak, A.; Sciacca, S.; D’Orazio, N.; Del Rio, D.; Galvano, F. A comprehensive meta-analysis on dietary flavonoid and lignan intake and cancer risk: Level of evidence and limitations. Mol. Nutr. Food Res. 2017, 61.
  51. Wang, Z.M.; Nie, Z.L.; Zhou, B.; Lian, X.Q.; Zhao, H.; Gao, W.; Wang, Y.S.; Jia, E.Z.; Wang, L.S.; Yang, Z.J. Flavonols intake and the risk of coronary heart disease: A meta-analysis of cohort studies. Atherosclerosis 2012, 222, 270–273.
  52. Godos, J.; Vitale, M.; Micek, A.; Ray, S.; Martini, D.; Del Rio, D.; Riccardi, G.; Galvano, F.; Grosso, G. Dietary Polyphenol Intake, Blood Pressure, and Hypertension: A Systematic Review and Meta-Analysis of Observational Studies. Antioxidants 2019, 8, 152.
  53. Cui, L.; Liu, X.; Tian, Y.; Xie, C.; Li, Q.; Cui, H.; Sun, C. Flavonoids, Flavonoid Subclasses, and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies. Nutrients 2016, 8, 350.
  54. Guo, K.; Liang, Z.; Liu, L.; Li, F.; Wang, H. Flavonoids intake and risk of prostate cancer: A meta-analysis of observational studies. Andrologia 2016, 48, 1175–1182.
  55. Menezes, R.; Dumont, J.; Schär, M.; Palma-Duran, S.A.; Combet, E.; Ruskovska, T.; Maksimova, V.; Pinto, P.; Rodriguez-Mateos, A.; Kaltsatou, A.; et al. Impact of Flavonols on Cardiometabolic Biomarkers: A Meta-Analysis of Randomized Controlled Human Trials to Explore the Role of Inter-Individual Variability. Nutrients 2017, 9, 117.
  56. Akhlaghi, M.; Ghobadi, S.; Mohammad Hosseini, M.; Gholami, Z.; Mohammadian, F. Flavanols are potential anti-obesity agents, a systematic review and meta-analysis of controlled clinical trials. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 675–690.
  57. Guo, W.; Gong, X.; Li, M. Quercetin Actions on Lipid Profiles in Overweight and Obese Individuals: A Systematic Review and Meta-Analysis. Curr. Pharm. Des. 2019, 25, 3087–3095.
  58. Huang, H.; Liao, D.; Dong, Y.; Pu, R. Clinical effectiveness of quercetin supplementation in the management of weight loss: A pooled analysis of randomized controlled trials. Diabetes Metab. Syndr. Obes. 2019, 12, 553–563.
  59. Huang, H.; Liao, D.; Dong, Y.; Pu, R. Effect of quercetin supplementation on plasma lipid profiles, blood pressure, and glucose levels: A systematic review and meta-analysis. Nutr. Rev. 2020, 78, 615–626.
  60. Mohammadi-Sartang, M.; Mazloom, Z.; Sherafatmanesh, S.; Ghorbani, M.; Firoozi, D. Effects of supplementation with quercetin on plasma C-reactive protein concentrations: A systematic review and meta-analysis of randomized controlled trials. Eur. J. Clin. Nutr. 2017, 71, 1033–1039.
  61. Ostadmohammadi, V.; Milajerdi, A.; Ayati, E.; Kolahdooz, F.; Asemi, Z. Effects of quercetin supplementation on glycemic control among patients with metabolic syndrome and related disorders: A systematic review and meta-analysis of randomized controlled trials. Phytother. Res. 2019, 33, 1330–1340.
  62. Ou, Q.; Zheng, Z.; Zhao, Y.; Lin, W. Impact of quercetin on systemic levels of inflammation: A meta-analysis of randomised controlled human trials. Int. J. Food Sci. Nutr. 2020, 71, 152–163.
  63. Pelletier, D.M.; Lacerte, G.; Goulet, E.D. Effects of quercetin supplementation on endurance performance and maximal oxygen consumption: A meta-analysis. Int. J. Sport Nutr. Exerc. Metab. 2013, 23, 73–82.
  64. Peluso, I.; Raguzzini, A.; Serafini, M. Effect of flavonoids on circulating levels of TNF-α and IL-6 in humans: A systematic review and meta-analysis. Mol. Nutr. Food Res. 2013, 57, 784–801.
  65. Somerville, V.; Bringans, C.; Braakhuis, A. Polyphenols and Performance: A Systematic Review and Meta-Analysis. Sports Med. 2017, 47, 1589–1599.
  66. Kimble, R.; Keane, K.M.; Lodge, J.K.; Howatson, G. Dietary intake of anthocyanins and risk of cardiovascular disease: A systematic review and meta-analysis of prospective cohort studies. Crit. Rev. Food Sci. Nutr. 2019, 59, 3032–3043.
  67. Kimble, R.; Jones, K.; Howatson, G. The effect of dietary anthocyanins on biochemical, physiological, and subjective exercise recovery: A systematic review and meta-analysis. Crit. Rev. Food Sci. Nutr. 2021, 1–15.
  68. Fallah, A.A.; Sarmast, E.; Jafari, T. Effect of dietary anthocyanins on biomarkers of glycemic control and glucose metabolism: A systematic review and meta-analysis of randomized clinical trials. Food Res. Int. 2020, 137, 109379.
  69. Bloedon, T.K.; Braithwaite, R.E.; Carson, I.A.; Klimis-Zacas, D.; Lehnhard, R.A. Impact of anthocyanin-rich whole fruit consumption on exercise-induced oxidative stress and inflammation: A systematic review and meta-analysis. Nutr. Rev. 2019, 77, 630–645.
  70. Shah, K.; Shah, P. Effect of Anthocyanin Supplementations on Lipid Profile and Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cholesterol 2018, 2018, 8450793.
  71. Araki, R.; Yada, A.; Ueda, H.; Tominaga, K.; Isoda, H. Differences in the Effects of Anthocyanin Supplementation on Glucose and Lipid Metabolism According to the Structure of the Main Anthocyanin: A Meta-Analysis of Randomized Controlled Trials. Nutrients 2021, 13, 2003.
  72. Fairlie-Jones, L.; Davison, K.; Fromentin, E.; Hill, A.M. The Effect of Anthocyanin-Rich Foods or Extracts on Vascular Function in Adults: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Nutrients 2017, 9, 908.
  73. Park, S.; Choi, M.; Lee, M. Effects of Anthocyanin Supplementation on Reduction of Obesity Criteria: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Nutrients 2021, 13, 2121.
  74. Sangsefidi, Z.S.; Mozaffari-Khosravi, H.; Sarkhosh-Khorasani, S.; Hosseinzadeh, M. The effect of anthocyanins supplementation on liver enzymes: A systematic review and meta-analysis of randomized clinical trials. Food Sci. Nutr. 2021, 9, 3954–3970.
  75. Daneshzad, E.; Shab-Bidar, S.; Mohammadpour, Z.; Djafarian, K. Effect of anthocyanin supplementation on cardio-metabolic biomarkers: A systematic review and meta-analysis of randomized controlled trials. Clin. Nutr. 2019, 38, 1153–1165.
  76. Ren, J.; An, J.; Chen, M.; Yang, H.; Ma, Y. Effect of proanthocyanidins on blood pressure: A systematic review and meta-analysis of randomized controlled trials. Pharmacol. Res. 2021, 165, 105329.
  77. Fujiwara, T.; Nishida, N.; Nota, J.; Kitani, T.; Aoishi, K.; Takahashi, H.; Sugahara, T.; Hato, N. Efficacy of chlorophyll c2 for seasonal allergic rhinitis: Single-center double-blind randomized control trial. Eur. Arch. Oto-Rhino-Laryngol. 2016, 273, 4289–4294.
  78. Montelius, C.; Erlandsson, D.; Vitija, E.; Stenblom, E.-L.; Egecioglu, E.; Erlanson-Albertsson, C. Body weight loss, reduced urge for palatable food and increased release of GLP-1 through daily supplementation with green-plant membranes for three months in overweight women. Appetite 2014, 81, 295–304.
  79. Balder, H.F.; Vogel, J.; Jansen, M.C.; Weijenberg, M.P.; van den Brandt, P.A.; Westenbrink, S.; van der Meer, R.; Goldbohm, R.A. Heme and chlorophyll intake and risk of colorectal cancer in the Netherlands cohort study. Cancer Epidemiol. Prev. Biomark. 2006, 15, 717–725.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/)
ScholarVision Creations
Feedback